Neurophet develops AI solutions for neurodegenerative diseases
Neurophet Inc., with expertise in neuroscience, has been focusing on developing and providing innovative medical solutions for helping patients suffering from neurological disorders. To achieve this mission, the company has applied state-of-the-art AI technologies to their expertise in neuroimaging, brain modelling and neuromodulation. They have been conducting research in imaging-based biomarkers for Alzheimer’s disease, which will be a valuable tool for clinical trials (surrogate biomarkers for drug response, disease progression and efficacy/safety monitoring) and prescription decisions for Alzheimer’s therapeutics, such as Lecanemab and Donanemab.
Neurophet provides medical-grade solutions including brain MRI imaging analysis and interpretation (brain atrophy, white matter hyperintensity) software “Neurophet AQUA” and brain PET scan analysis (Amyloid/Tau/FDG PET tracer deposition) software “Neurophet SCALE PET”, approved by international regulatory bodies including US-FDA, CE, Japanese PMDA and Korean MFDS.
Neurophet has set its top priority to helping patients suffering from neurological diseases. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain’s health and pioneer solutions for brain diseases with AI technology.
Product profile
Neurophet AQUA is a medical-grade AI software that assists neuroradiologists and clinicians in the accurate diagnosis of neurodegenerative diseases, including dementia, by providing brain MRI analysis for brain atrophy and white matter hyperintensity within five minutes.
It encompasses two primary functions: firstly, it offers brain segmentation into 126 regions of interest (ROI) from T1-weighted images, facilitating brain volume quantification and atrophy assessment, which is a key indicator of neurodegenerative diseases, such as Alzheimer’s. Additionally, it provides a longitudinal feature for tracking changes in brain volume over time. Secondly, from T2-FLAIR images, it accurately segments and quantifies white matter hyperintensity (WMH) caused by vascular degeneration, while also providing a severity score based on the Fazekas scale. The brain MRI analysis can support precise diagnosis of neurodegenerative disorders and contribute to time-saving for the neuroimaging interpretation with comparable accuracy.
The solution has been validated through various peer-reviewed published studies and provides a diverse range of nine report formats and normative percentile information derived from both Asian and Western populations. Furthermore, it is compatible with various MRI scanners – validated across 16 different models – making it a versatile tool for neuroimaging analysis. The software can be fully integrated with PACS in radiology departments.
New features for Alzheimer’s therapeutics-related (e.g. Lecanemab and Donanemab) neuroimaging technologies, including Amyloid-Related Image Abnormalities (ARIA) and MRI-based amyloid-PET positivity prediction, are under development and will become a valuable tool for prescription decisions and screening of subjects for Alzheimer’s therapeutics.
- For more information, visit: https://www.neurophet.com
